Zogenix 2015 Expectations and Developments Drive Price Upward: Analyst Report Issued by BrokerBank Securities, Inc.

NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Zogenix Inc. ZGNX is a California-based pharmaceutical company that develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company's two main products include Zohydro (a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain) and Relday (an injectable formulation of risperidone formulated to treat the symptoms of schizophrenia and bipolar disorder, and which is in a Phase I clinical trial). Zogenix was founded in 2006 with its headquarter located in San Diego, California.

Since its IPO in 2010, Zogenix stock reached its peak twice, one of them was on Feb 10^th 2014 at $4.7. The stock had been experiencing poor performance throughout 2014 despite the fact that its Q3 result outperformed the street's expectation. However, the stock has shown positive signs recently, and it seems to be a good time to enter the market due to its current underprice and several catalysts for growth in 2015.

The November 2014 issue of the Journal of Pain Research published a long-term, open-label study that explained the safety, effectiveness, and tolerability of Zohydro ER.

Further, Zogenix has participated in multiple healthcare conferences that took place in New York City, including the Stifel 2014 Healthcare Conference in November 2014, and the Oppenheimer 25^th Annual Healthcare Conference in December 2014.

For the full research report with analyst comments, recommendation and price target on Zogenix Inc. please follow the link. There is no cost obligation required to view analyst report:

http://bit.ly/-ZGNX-AnalystReport

Copy and paste to browser may be required.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Not Financial Advice

BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zogenix-2015-expectations-and-developments-drive-price-upward-analyst-report-issued-by-brokerbank-securities-inc-300015342.html

SOURCE BrokerBank Securities, Inc.